Jump to content Jump to main menu Jump to sub menu

Archive

13 October 2011 - QED invited to present at Henry Stewart’s SOP Conference

QED’s Director of UK Operations, Susan Ollier, will present at the Henry Stewart’s SOP conference on 7th November in London.  Read more »

15 April 2011 - QED win international CNS trial

QED are delighted to announce that they have been selected for an international observational study in Parkinson’s Disease.  The study will run for 5 years and QED will be responsible for sites in the UK, Italy, Germany and Austria.  QED’s Director International Operations, Nazira Maruf said “We are extremely pleased to be involved in this project which is helping to combat this progressive neurological condition.  Our expertise on the ground in each of the participating countries, coupled with our central expertise will ensure we can deliver this trial successfully”.

25 February 2011 - QED awarded important study

QED has been awarded a critical proof of concept study in the area of liver disease.  QED will be responsible for the project management and clinical monitoring of this phase II trial.  QED Director UK Operations, Susan Ollier, commented “This is a highly interesting study and QED has current experience of working on another phase II study being run in a number of key Hepatology centres.  We are delighted to be able to build on these existing current links to the right institutions that could be involved in this latest trial”.  QED’s involvement in this study is planned to last until August 2012.

21 September 2011 - QED receives 2 Finalist nominations in the PharmaTimes Awards 2011, Project Management Category

QED is proud to announce that two of its Clinical Study Managers have been shortlisted as Finalists in the PharmaTimes Awards 2011 CRO Project Management Cateogory.  Read more »

10 March 2011 - QED expands Observational study experience

QED is pleased to announce that it has further extended it’s Observational study experience with the award of an important project in Chronic Obstructive Pulmonary Disease.  The study will run in the UK for 18 months.  Susan Ollier, QED Director UK Operations, commented “We are delighted to be selected for this study, which enhances both our Observational trial and Respiratory therapeutic area expertise”.